| NCT03262974 |
Effect of Pharmacogenetics on Imatinib Plasma Level and Response |
https://ClinicalTrials.gov/show/NCT03262974 |
Active, not recruiting |
Assiut University |
2021-05-31 |
| NCT03075969 |
Phase IV EORTC Quality of Life Module for Patients With Chronic Myeloid Leukemia |
https://ClinicalTrials.gov/show/NCT03075969 |
Active, not recruiting |
Gruppo Italiano Malattie EMatologiche dell’Adulto |
2019-03-16 |
| NCT03045120 |
Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States |
https://ClinicalTrials.gov/show/NCT03045120 |
Recruiting |
Bristol-Myers Squibb |
2021-01-31 |
| NCT02977312 |
Study of Cemivil® (Imatinib) in Chronic Myeloid Leukemia Patients in Jordan |
https://ClinicalTrials.gov/show/NCT02977312 |
Completed |
Hikma Pharmaceuticals LLC |
2015-02-28 |
| NCT02896829 |
Follow-up of the Persistence of the Complete Molecular Remission After Stopping Imatinib Chronic Myeloid Leukemia |
https://ClinicalTrials.gov/show/NCT02896829 |
Completed |
University Hospital, Bordeaux |
2019-04-30 |
| NCT02895542 |
Preparatory Work to Assess Adherence to Oral Chemotherapy |
https://ClinicalTrials.gov/show/NCT02895542 |
Completed |
Wake Forest University Health Sciences |
2017-04-28 |
| NCT02869256 |
Regional Central Database Recording of Chronic Myeloid Leukemia |
https://ClinicalTrials.gov/show/NCT02869256 |
Recruiting |
Institut Bergonié |
2024-01-31 |
| NCT02767388 |
Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery |
https://ClinicalTrials.gov/show/NCT02767388 |
Completed |
University of Nebraska |
2017-12-11 |
| NCT02734823 |
Long Term Effects of Tyrosine Kinase Inhibitor Therapy on Ovarian Reserve and Fertility in Patients With Chronic Myeloid Leukemia or Gastrointestinal Stromal Tumor |
https://ClinicalTrials.gov/show/NCT02734823 |
Recruiting |
University of Southern California |
2020-03-01 |
| NCT02733445 |
Metabolic Outcomes in Patients Receiving Tyrosine Kinase Inhibitor (TKI) Therapy With Dasatinib or Nilotinib |
https://ClinicalTrials.gov/show/NCT02733445 |
Completed |
Bristol-Myers Squibb |
2015-12-31 |
| NCT01351545 |
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) |
https://ClinicalTrials.gov/show/NCT01351545 |
Recruiting |
Center for International Blood and Marrow Transplant Research |
2021-10-31 |
| NCT02546791 |
Frequency and Severity of Pleural Effusion Associated With the Use of Dasatinib in Patients With Chronic Myeloid Leukemia. A Descriptive, Mexican Multicenter Study |
https://ClinicalTrials.gov/show/NCT02546791 |
Completed |
Bristol-Myers Squibb |
2016-11-30 |
| NCT02546375 |
A Study To Describe The Real World Use Of Bosutinib In The UK And Netherlands |
https://ClinicalTrials.gov/show/NCT02546375 |
Completed |
Pfizer |
2017-01-16 |
| NCT02501330 |
Safety And Efficacy Of Bosutinib |
https://ClinicalTrials.gov/show/NCT02501330 |
Recruiting |
Pfizer |
2023-09-04 |
| NCT02455024 |
An Observational Registry to Evaluate the Incidence of and Risk Factors for Vascular Occlusive Events Associated With ICLUSIG® |
https://ClinicalTrials.gov/show/NCT02455024 |
Recruiting |
Takeda |
2020-09-30 |
| NCT02448095 |
Retrospective Evaluation of CML Patients in the National Compassionate Program |
https://ClinicalTrials.gov/show/NCT02448095 |
Recruiting |
Gruppo Italiano Malattie EMatologiche dell’Adulto |
2018-12-31 |
| NCT02389972 |
Effectiveness of Dasatinib in Adult Patients With Chronic Myeloid Leukemia in China: A Multicenter, Registry Study |
https://ClinicalTrials.gov/show/NCT02389972 |
Completed |
Bristol-Myers Squibb |
2017-07-13 |
| NCT02363868 |
Healthcare Costs Among Patients With CML Receiving Dasatinib or Nilotinib in a Commercial and Medicare Population |
https://ClinicalTrials.gov/show/NCT02363868 |
Completed |
Bristol-Myers Squibb |
2014-11-30 |
| NCT02348957 |
Treating Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) With Dasatinib |
https://ClinicalTrials.gov/show/NCT02348957 |
Completed |
Onco Medical Consult GmbH |
2019-03-31 |
| NCT02338479 |
Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT02338479 |
Active, not recruiting |
Center for International Blood and Marrow Transplant Research |
2020-02-29 |
| NCT02269267 |
The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study) |
https://ClinicalTrials.gov/show/NCT02269267 |
Active, not recruiting |
Medical College of Wisconsin |
2020-09-30 |
| NCT02222272 |
Effect of 2nd Gen TKI in CML |
https://ClinicalTrials.gov/show/NCT02222272 |
Completed |
European Group for Blood and Marrow Transplantation |
2014-03-19 |
| NCT02164903 |
LEONIDAS: Quality of Life Study in Chronic Myeloid Leukemia Patients |
https://ClinicalTrials.gov/show/NCT02164903 |
Active, not recruiting |
Gruppo Italiano Malattie EMatologiche dell’Adulto |
2017-01-25 |
| NCT02161978 |
Vascular Dysfunction and Antiangiogenic Therapy |
https://ClinicalTrials.gov/show/NCT02161978 |
Completed |
University Hospital, Angers |
2018-12-12 |
| NCT02057185 |
Occupational Status and Hematological Disease |
https://ClinicalTrials.gov/show/NCT02057185 |
Active, not recruiting |
Gruppo Italiano Malattie EMatologiche dell’Adulto |
2019-03-31 |
| NCT02016833 |
Development of Immunological Assays for the Evaluation of Tumor Antigen Specific Immunity |
https://ClinicalTrials.gov/show/NCT02016833 |
Completed |
PX Biosolutions |
2014-06-30 |
| NCT01860456 |
TyrosIne Kinase Inhibitors in Chronic Myeloid Leukemia: Efficacy and Tolerability. The TIKlet Study |
https://ClinicalTrials.gov/show/NCT01860456 |
Active, not recruiting |
University of Pisa |
2021-05-31 |
| NCT01805843 |
Pulmonary Vasculopathy Under Second-line Therapy of Chronic Myeloid Leukemia |
https://ClinicalTrials.gov/show/NCT01805843 |
Completed |
Medical University of Graz |
2015-06-30 |
| NCT01761890 |
Front-line Treatment of BCR-ABL+ Chronic Myeloid Leukemia (CML) With Dasatinib |
https://ClinicalTrials.gov/show/NCT01761890 |
Recruiting |
Gruppo Italiano Malattie EMatologiche dell’Adulto |
2018-12-31 |
| NCT01752062 |
Observational Study of Conception/Pregnancy in Adult Patients With CML Treated With Tyrosine Kinase Inhibitors |
https://ClinicalTrials.gov/show/NCT01752062 |
Recruiting |
Gruppo Italiano Malattie EMatologiche dell’Adulto |
2018-12-31 |
| NCT01699217 |
Front-line Nilotinib Treatment of BCR-ABL+ Chronic Myeloid Leukaemia in Chronic Phase |
https://ClinicalTrials.gov/show/NCT01699217 |
Recruiting |
Gruppo Italiano Malattie EMatologiche dell’Adulto |
2019-11-30 |
| NCT01490853 |
Follow-up of Ph+ Chronic Myleoid Leukemia Patients in Complete Cytogenetic Response With Interferon Based Therapy |
https://ClinicalTrials.gov/show/NCT01490853 |
Completed |
Università degli Studi di Brescia |
2012-01-31 |
| NCT01475110 |
Observational Study in Adults With Imatinib-resistant/Intolerant Chronic Myeloid Leukemia Treated With Nilotinib |
https://ClinicalTrials.gov/show/NCT01475110 |
Recruiting |
Gruppo Italiano Malattie EMatologiche dell’Adulto |
2018-12-31 |
| NCT01437202 |
Pharmacogenomics Validation for Imatinib in Chronic Myeloid Leukemia |
https://ClinicalTrials.gov/show/NCT01437202 |
Completed |
Asan Medical Center |
2012-09-30 |
| NCT01394666 |
Non-interventional Treatment Patterns Study in Chronic Phase Chronic Myelogenous Leukemia (CP-CML) |
https://ClinicalTrials.gov/show/NCT01394666 |
Completed |
Bristol-Myers Squibb |
2012-12-31 |
| NCT04150471 |
Assess Long-term Feasibility of Reduced Dose Dasatinib in Chronic Phase Chronic Myeloid Leukemia Patients |
https://ClinicalTrials.gov/show/NCT04150471 |
Recruiting |
Seoul St. Mary’s Hospital |
2020-12-30 |
| NCT04104035 |
Leukemic Stem Cell Detection for Chronic Myeloid Leukemia Patients With Major Molecular Response |
https://ClinicalTrials.gov/show/NCT04104035 |
Recruiting |
Ankara University |
2021-01-31 |
| NCT04089839 |
A Study of Dasatinib Management Among CP-CML (Chronic Phase, Chronic Myeloid Leukemia) Participants Initiating Dasatinib in a Real Life Setting |
https://ClinicalTrials.gov/show/NCT04089839 |
Active, not recruiting |
Bristol-Myers Squibb |
2020-10-31 |
| NCT04048564 |
Observational Study on CML Patients in Any Phase of the Disease Treated With Ponatinib (Iclusig®) |
https://ClinicalTrials.gov/show/NCT04048564 |
Recruiting |
Incyte Corporation |
2022-02-28 |
| NCT03996096 |
Tyrosine Kinase Inhibitor Withdrawal Syndrome in CML Patients: Observatory Trial Studying the Biological Factors. |
https://ClinicalTrials.gov/show/NCT03996096 |
Recruiting |
University Hospital, Caen |
2020-07-31 |
| NCT03933852 |
Observational Study on Chronic Myeloid Leukemia Patients in Any Phase Treated With Ponatinib (Iclusig®) at Any Dose |
https://ClinicalTrials.gov/show/NCT03933852 |
Recruiting |
University of Jena |
2022-12-31 |
| NCT03885830 |
Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients |
https://ClinicalTrials.gov/show/NCT03885830 |
Active, not recruiting |
UNC Lineberger Comprehensive Cancer Center |
2020-12-31 |
| NCT03860376 |
Ex Vivo Drug Sensitivity Testing and Mutation Profiling |
https://ClinicalTrials.gov/show/NCT03860376 |
Recruiting |
Florida International University |
2022-12-15 |
| NCT03678454 |
Iclusig® (Ponatinib) in Clinical Practice for the Treatment of Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia in Belgium |
https://ClinicalTrials.gov/show/NCT03678454 |
Recruiting |
Incyte Corporation |
2022-03-31 |
| NCT03540654 |
Budget Impact Analysis of Discontinuing Tyrosin Kinase Inhibitors in Patients With Chronic Myeloid Leukemia Achieving a Complete Molecular Response by Using Probabilistic Markov Approach |
https://ClinicalTrials.gov/show/NCT03540654 |
Completed |
University Hospital, Bordeaux |
2018-10-31 |
| NCT03481868 |
EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors |
https://ClinicalTrials.gov/show/NCT03481868 |
Recruiting |
University Hospital, Clermont-Ferrand |
2021-02-10 |
| NCT03454503 |
Effectiveness and Safety Study of Generic Imatinib in Chronic Myeloid Leukemia Patients in Egypt |
https://ClinicalTrials.gov/show/NCT03454503 |
Active, not recruiting |
Hikma Pharmaceuticals LLC |
2021-01-31 |
| NCT03421626 |
Clinical Evaluation of a Test for Monitoring Patients Diagnosed With Chronic Myeloid Leukemia (CML) |
https://ClinicalTrials.gov/show/NCT03421626 |
Completed |
Cepheid |
2018-08-20 |
| NCT01252589 |
Patient Reported Outcomes in Chronic Myeloid Leukemia |
https://ClinicalTrials.gov/show/NCT01252589 |
Completed |
Gruppo Italiano Malattie EMatologiche dell’Adulto |
2013-09-30 |
| NCT01244750 |
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting |
https://ClinicalTrials.gov/show/NCT01244750 |
Active, not recruiting |
Bristol-Myers Squibb |
2020-01-30 |
| NCT01215487 |
A Study Investigating the Predictive Value of Philadelphia Positive Stem Cell Properties in Newly Diagnosed Patients With Chronic Myeloid Leukemia in Chronic Phase Receiving Treatment With Imatinib |
https://ClinicalTrials.gov/show/NCT01215487 |
Recruiting |
University of British Columbia |
2022-01-31 |
| NCT01199562 |
Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT01199562 |
Completed |
City of Hope Medical Center |
2013-12-31 |
| NCT01188278 |
Treatment With Second Generation Tyrosine Kinase Inhibitors (2G TKI) Post Imatinib Failure Survey |
https://ClinicalTrials.gov/show/NCT01188278 |
Completed |
Bristol-Myers Squibb |
2013-01-31 |
| NCT01046305 |
Symptom Burden in Chronic Myeloid Leukemia (CML) |
https://ClinicalTrials.gov/show/NCT01046305 |
Active, not recruiting |
M.D. Anderson Cancer Center |
2020-11-30 |
| NCT00947830 |
Investigating Intracellular and Plasma Imatinib Levels in Chronic Myeloid Leukemia |
https://ClinicalTrials.gov/show/NCT00947830 |
Completed |
McMaster University |
2012-04-30 |
| NCT00898755 |
Collecting and Storing Tissue From Young Patients With Cancer |
https://ClinicalTrials.gov/show/NCT00898755 |
Completed |
Children’s Oncology Group |
2008-07-17 |
| NCT00898079 |
Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer |
https://ClinicalTrials.gov/show/NCT00898079 |
Completed |
Children’s Oncology Group |
2018-06-30 |
| NCT00896129 |
Mid-to Long-Term Outcomes in Chronic Myeloid Leukemia (CML) Patients With Complete Cytogenetic Response After Imatinib as First Line Therapy |
https://ClinicalTrials.gov/show/NCT00896129 |
Completed |
Gruppo Italiano Malattie EMatologiche dell’Adulto |
2010-12-31 |
| NCT03647215 |
CALLS: CML and Ph+ALL Low Level Mutation Prevalence Survey |
https://ClinicalTrials.gov/show/NCT03647215 |
Recruiting |
Incyte Corporation |
2020-06-30 |
| NCT00816114 |
Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial |
https://ClinicalTrials.gov/show/NCT00816114 |
Recruiting |
M.D. Anderson Cancer Center |
2020-06-30 |
| NCT03709017 |
Iclusig PMS in CML or Ph+ALL Patients |
https://ClinicalTrials.gov/show/NCT03709017 |
Recruiting |
Korea Otsuka Pharmaceutical Co., Ltd. |
2023-06-30 |
| NCT00632255 |
Long Term Therapy With Imatinib: Development of Late Side Effects and Compliance to Treatment |
https://ClinicalTrials.gov/show/NCT00632255 |
Completed |
Imperial College London |
2009-05-31 |
| NCT00569842 |
Investigation of the Cylex® ImmuKnow® Assay |
https://ClinicalTrials.gov/show/NCT00569842 |
Completed |
Indiana University |
2010-02-28 |
| NCT00513175 |
Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia |
https://ClinicalTrials.gov/show/NCT00513175 |
Completed |
University of California, San Francisco |
NA |
| NCT00429910 |
Natural History Study of Patients With Chronic Myelogenous Leukemia |
https://ClinicalTrials.gov/show/NCT00429910 |
Completed |
Dana-Farber Cancer Institute |
2005-09-30 |
| NCT00257647 |
Use of SV40 Vectors to Treat Chronic Myeloid Leukemia (CML) |
https://ClinicalTrials.gov/show/NCT00257647 |
Completed |
Hadassah Medical Organization |
NA |
| NCT00159003 |
Analysis of Genetic Factors Related to Predisposition and Prognosis of Hematological Malignancies in Israel |
https://ClinicalTrials.gov/show/NCT00159003 |
Completed |
Hadassah Medical Organization |
2017-07-01 |
| NCT00001432 |
The Collection of Peripheral Blood Lymphocytes and Marrow Progenitor Cells From Normal Volunteers and Volunteers With Lymphoid or Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00001432 |
Completed |
National Institutes of Health Clinical Center (CC) |
NA |